Foghorn Therapeutics Inc (FHTX) — Capital Reinvestment Ratio
Latest as of March 2022:
0.00x
Foghorn Therapeutics Inc (FHTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($271.53 Million) in capital expenditures ($247.00K). See free cash flow generation of Foghorn Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$271.53 Million
USD
Capital Expenditures
$247.00K
USD
Data as of
Mar 2022
Most recent filing
Foghorn Therapeutics Inc Capital Reinvestment Ratio (2022–2022)
This chart tracks Foghorn Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Foghorn Therapeutics Inc (2022–2022)
Year-by-year Capital Reinvestment Ratio for Foghorn Therapeutics Inc from 2022 to 2022. For live market cap and broader valuation context, see Foghorn Therapeutics Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | $193.61 Million | $1.21 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow